| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00059-017-4548-3 |
| P698 | PubMed publication ID | 28229200 |
| P2093 | author name string | M Borggrefe | |
| I Akin | |||
| B Rudic | |||
| J Kuschyk | |||
| P2860 | cites work | 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management | Q38038846 |
| Opportunity to increase life span in narrow QRS cardiac resynchronization therapy recipients by deactivating ventricular pacing: evidence from randomized controlled trials. | Q38377406 | ||
| Long-Term Risk for Device-Related Complications and Reoperations After Implantable Cardioverter-Defibrillator Implantation: An Observational Cohort Study | Q39804227 | ||
| Combined leadless pacemaker and subcutaneous implantable defibrillator therapy: feasibility, safety, and performance | Q39949073 | ||
| Improvement of long-term survival by cardiac contractility modulation in heart failure patients: A case-control study. | Q40084676 | ||
| Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure | Q40560008 | ||
| Prediction of Appropriate Shocks Using 24-Hour Holter Variables and T-Wave Alternans After First Implantable Cardioverter-Defibrillator Implantation in Patients With Ischemic or Nonischemic Cardiomyopathy | Q40749463 | ||
| [2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac Death. The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the | Q40826271 | ||
| Long-term survival with Cardiac Contractility Modulation in patients with NYHA II or III symptoms and normal QRS duration | Q40892104 | ||
| Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry. | Q41020440 | ||
| Subcutaneous implantable cardioverter-defibrillator: First single-center experience with other cardiac implantable electronic devices | Q41670602 | ||
| Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure | Q42680030 | ||
| Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. | Q43540422 | ||
| Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction | Q44444685 | ||
| Vagus Nerve Stimulation for the Treatment of Heart Failure: The INOVATE-HF Trial | Q44904423 | ||
| Acute and mid-term outcomes of transvenous implant of a new left ventricular quadripolar lead versus bipolar leads for cardiac resynchronization therapy: results from a single-center prospective database | Q44951216 | ||
| Complications leading to surgical revision in implantable cardioverter defibrillator patients: comparison of patients with single-chamber, dual-chamber, and biventricular devices | Q44981372 | ||
| Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure: The DEFEAT-HF Study | Q45023716 | ||
| Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure: results of the ANTHEM-HF trial | Q46545273 | ||
| Cardiac contractility modulation in heart failure patients: Randomized comparison of signal delivery through one vs. two ventricular leads | Q47664449 | ||
| Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. | Q49168539 | ||
| Communicating Antitachycardia Pacing-Enabled Leadless Pacemaker and Subcutaneous Implantable Defibrillator. | Q51418447 | ||
| Multipoint left ventricular pacing in a single coronary sinus branch improves mid-term echocardiographic and clinical response to cardiac resynchronization therapy. | Q53477060 | ||
| Who should receive the subcutaneous implanted defibrillator?: The subcutaneous implantable cardioverter defibrillator (ICD) should be considered in all ICD patients who do not require pacing. | Q53653830 | ||
| Safety and Efficacy of a Totally Subcutaneous Implantable-Cardioverter Defibrillator | Q56657754 | ||
| Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction | Q58011025 | ||
| Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH) | Q74172803 | ||
| Multipoint pacing by a left ventricular quadripolar lead improves the acute hemodynamic response to CRT compared with conventional biventricular pacing at any site | Q86607956 | ||
| Prognostic importance of defibrillator shocks in patients with heart failure | Q24631203 | ||
| Electrical vagus nerve stimulation for the treatment of chronic heart failure | Q26851442 | ||
| Prediction of mortality in clinical practice for medicare patients undergoing defibrillator implantation for primary prevention of sudden cardiac death | Q30418849 | ||
| Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone | Q33145337 | ||
| ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities | Q33156332 | ||
| 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). | Q33164685 | ||
| A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias | Q33175452 | ||
| Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator | Q33585210 | ||
| Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry | Q33827116 | ||
| Effects of cardiac resynchronization therapy on long-term quality of life: an analysis from the CArdiac Resynchronisation-Heart Failure (CARE-HF) study | Q34016343 | ||
| Impact of cardiac contractility modulation on left ventricular global and regional function and remodeling. | Q34093447 | ||
| A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure | Q34164055 | ||
| Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure | Q34211213 | ||
| Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure | Q34321811 | ||
| New devices in heart failure: an European Heart Rhythm Association report: developed by the European Heart Rhythm Association; endorsed by the Heart Failure Association | Q34387086 | ||
| The effect of cardiac resynchronization on morbidity and mortality in heart failure | Q34400885 | ||
| Efficacy and survival in patients with cardiac contractility modulation: long-term single center experience in 81 patients | Q34461751 | ||
| 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribut | Q34527664 | ||
| ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiolo | Q34560910 | ||
| Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years | Q34624387 | ||
| Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure | Q34749450 | ||
| Cardiac contractility modulation electrical signals improve myocardial gene expression in patients with heart failure | Q34775553 | ||
| Cardiac contractility modulation in non-responders to cardiac resynchronization therapy | Q34822810 | ||
| Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial | Q35083803 | ||
| The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy | Q35367149 | ||
| Rationale, objectives, and design of the EUTrigTreat clinical study: a prospective observational study for arrhythmia risk stratification and assessment of interrelationships among repolarization markers and genotype | Q35768561 | ||
| Clinical Risk Stratification for Primary Prevention Implantable Cardioverter Defibrillators | Q36057430 | ||
| Vagus nerve stimulation in experimental heart failure | Q37200527 | ||
| Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy | Q37246567 | ||
| An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure | Q37374291 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | German | Q188 |
| P304 | page(s) | 151-161 | |
| P577 | publication date | 2017-02-22 | |
| P1433 | published in | Herz | Q2143725 |
| P1476 | title | [Current impact of cardiac implantable electronic devices]. | |
| P478 | volume | 42 |
Search more.